Drug Trial Radar · NCT06228846
An Phase I Study of YY001 in Patients with Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jul 14, 2022
Primary completion
Apr 30, 2024
Study completion May 30, 2024
Sponsor
- Lead sponsor
- Shanghai Yuyao Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The safety and tolerability of YY001 in the treatment of patients with advanced solid tumors were evaluated, and the possible dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II clinical dose (RP2D) were observed.
Conditions
- Advanced Solid Tumor
Interventions
YY001Drug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicityTime frame: Up to 24 days after the initial drug administration
- Maximum tolerated doseTime frame: Up to 24 days after the initial drug administration
- Recommended Dose for Phase II Clinical Studies (RP2D)Time frame: Up to 24 days after the initial drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.